ReviewFrontiers in immunology2022
Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Successful Treatment of Cutaneous Manifestations of Blau Syndrome with UVA-1 Phototherapy in a Paediatric Patient.Acta dermato-venereologica · 2026Article
- NOD2-Related Multisystem Inflammatory Disorders and Recent Advances.Current rheumatology reports · 2026Review
- A case report: Guillain-Barré syndrome probably associated with TNF inhibitor in Blau syndrome.BMC pediatrics · 2026Article
- Mechanisms outpacing medicine in autoinflammatory diseases.Frontiers in immunology · 2026Review
- Potential benefits of JAK inhibitor therapy in Blau syndrome: a case report.Frontiers in immunology · 2025Article
- Review
- Management of Blau syndrome: review and proposal of a treatment algorithm.European journal of pediatrics · 2024Review
- Pulmonary granulomas confirmed in Blau syndrome using TBLC specimens: Case report.Frontiers in medicine · 2024Article
- Comprehensive clinical phenotype, genotype and therapy in Yao syndrome.Frontiers in immunology · 2024Article
- Editorial: Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseases.Frontiers in immunology · 2024Article
- Clinical Disease States Related to Mutations of the NOD2 Gene: A Case Report and Literature Review.Cureus · 2023Article
- A Chinese girl of Blau syndrome with renal arteritis and a literature review.Pediatric rheumatology online journal · 2023Review
- Granulomatous inflammation in inborn errors of immunity.Frontiers in pediatrics · 2023Review
- Case Report: Methotrexate and hydroxychloroquine in combination for the treatment of NOD2-mutation-associated Blau syndrome.Frontiers in immunology · 2023Article
- Implications of combinedFrontiers in immunology · 2023Article
- Retinopathy as an initial sign of hereditary immunological diseases: report of six families and challenges in eye clinic.Frontiers in immunology · 2023Article
- Elevated G-CSF, IL8, and HGF in patients with definite Meniere's disease may indicate the role of NET formation in triggering autoimmunity and autoinflammation.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blau syndrome is a systemic autoinflammatory granulomatous disease caused by mutations in the nucleotide-binding oligomerization domain 2 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.